Patents Examined by T. Cunningham
-
Patent number: 5229667Abstract: A delay unit incorporated in a standard cell type semicustom-made integrated circuit comprises a plurality of complementary inverting circuits coupled in cascade for introducing a time delay into propagation of a signal, and a lead circuit coupled to one of the complementary inverting circuits for increasing the time delay, and the plurality of complementary inverting circuits and the load circuit are formed in and one a plurality of rectangular active areas defined by a thick field oxide film grown on a major surface of a semiconductor substrate, wherein the thick field oxide film penetrates into two of the rectangular active areas so as to form respective bifurcated portions, one of the complementary inverting circuits and the load circuit being formed in the bifurcated portions so that large channel resistance of the complementary inverting circuit and large capacitance of the load circuit are easily produced without changing the arrangement of the rectangular active areas.Type: GrantFiled: August 12, 1991Date of Patent: July 20, 1993Assignee: NEC CorporationInventor: Norie Shimizu
-
Patent number: 5223254Abstract: Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.Type: GrantFiled: September 20, 1988Date of Patent: June 29, 1993Assignee: Praxis Biologics, Inc.Inventors: Peter R. Paradiso, Stephen W. Hildreth, Branda T. Hu, Antonia Martin-Gallardo, Rasappa Arumugham
-
Patent number: 5223417Abstract: Disclosed herein is a method for transforming human B-cells preferably by infecting them with Epstein-Barr virus followed by transforming the Epstein Barr virus infected cells with an activated human ras gene. The transformed cells are useful for producing human monoclonal antibodies either without further manipulation or after fusion with antibody-secreting cells.Type: GrantFiled: November 8, 1991Date of Patent: June 29, 1993Assignee: New York UniversityInventors: Riccardo Dalla-Favera, Stephanie Seremetis
-
Patent number: 5223427Abstract: Murine hybridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.Type: GrantFiled: March 9, 1988Date of Patent: June 29, 1993Assignee: The Scripps Research InstituteInventors: Thomas S. Edgington, James H. Morrissey
-
Patent number: 5214317Abstract: An electrical circuit is disclosed which implements a CMOS to ECL translator with an incorporated latch. The invention provides a circuit which uses a small number of devices, and provides fast transition times with low power consumption.Type: GrantFiled: May 4, 1992Date of Patent: May 25, 1993Assignee: National Semiconductor CorporationInventor: Thai M. Nguyen
-
Patent number: 5209929Abstract: Antigenic surface proteins from the intraerythrocytic merozoite stage of Babesia bigemina have been isolated using cell fusions and monoclonal antibodies produced thereby. Immunization of mammals, such as bovines, with purified isolates induces an immunological response that is effective to reduce pathological effects of babesiosis induced by Babesia bigemina. Diagnostic kits using monoclonal antibodies and antigenic surface proteins of Babesia bigemina are also disclosed.Type: GrantFiled: March 1, 1991Date of Patent: May 11, 1993Assignee: Washington State University Research FoundationInventors: Travis McGuire, Terry McElwain, Lance Perryman, William Davis
-
Patent number: 5202116Abstract: The present invention is directed to the use of a recently discovered cytokine, Oncostatin M, to control endothelial cell immunogenicity, fibrinolytic activity and proliferation, and to its use in the treatment of a variety of human vascular and immune system disorders involving the vascular endothelium. The method of the invention includes the use of mature, hybrid, modified or truncated forms of Oncostatin M as well as Oncostatin M analogs. The invention is described by way of examples in which the efficacy of such compounds is evaluated using various in vitro assay systems.Type: GrantFiled: April 10, 1989Date of Patent: April 13, 1993Assignee: OncogenInventors: Thomas J. Brown, Paul R. Gladstone
-
Patent number: 5196352Abstract: A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N G y V l G n V l G u T r I e S r P o G y A p G y A g T r P e P o L s A g-Gly-Gln-Thr-X-Val-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Fly-Lys-Phe-AS p (wherein X is undefined). The HCBV protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g. Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyses the cis-trans isomerization of proline-containing peptide bonds.Type: GrantFiled: June 27, 1991Date of Patent: March 23, 1993Assignee: Merck & Co., Inc.Inventors: John J. Siekierka, Hsuen-Yun Hung, Marie J. Staruch, Nolan H. Sigal, Richard A. Mumford
-
Patent number: 5194425Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X.sup.1 MHC.sup.2 peptide or MHC.sup.2 peptide.sup.1 X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; .sup.1 represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and .sup.2 represents a covalent bond, a noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.Type: GrantFiled: June 21, 1989Date of Patent: March 16, 1993Assignee: Anergen, Inc.Inventors: Somesh D. Sharma, L. Bernard Lerch, Brian R. Clark
-
Patent number: 5192538Abstract: This invention relates to stable forms of peptide antigens of T. ovis suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by expression of DNA coding therefor in a recombinant host cell. Aspects of the invention include DNA encoding the antigens, vectors containing the DNA and hosts which express the antigens.Type: GrantFiled: January 3, 1992Date of Patent: March 9, 1993Assignees: Pitman-Moore New Zealand Limited, The University of Melbourne, Her Majesty The Queen in right of New Zealand through the Ministry of Agriculture & FisheriesInventors: Gavin B. L. Harrison, Robert P. Dempster, Michael D. Rickard, Marshall W. Lightowlers, David D. Heath, Stephen B. Lawrence, Kim L. O'Hoy
-
Patent number: 5191233Abstract: In a flip-flop type level-shift circuit, a P-channel MOS transistor whose gate and drain are tied together is connected between a higher potential power supply terminal and a gate of an output stage P-channel MOS transistor. The P-channel MOS transistor together with the output stage P-channel MOS transistor constitutes a current-mirror circuit. The level-shift circuit can provide a constant-current output as high level output, thus making it unnecessary to include a high resistance protection resistor, which has hitherto been connected to an output terminal of the level-shift circuit to prevent destruction of the circuit caused by short-circuiting of the output, as well as permitting increase of the intergration density, reduction of the size and cost and improvement of the reliability of the circuit.Type: GrantFiled: March 6, 1992Date of Patent: March 2, 1993Assignee: NEC CorporationInventor: Masaji Nakano
-
Patent number: 5182520Abstract: In an apparatus for non-linear de-emphasis of an input signal, an amplitude limiting signal is obtained by subtracting a high-pass filtered and amplitude limited input signal from the original input signal, then the amplitude limiting signal is amplified with a gain determined by the amplitude of the amplitude limiting signal and subtracted from the input signal to provide a non-linearly de-emphasized signal with an improved signal-to-noise ratio and without substantial deterioration in high frequency small amplitude components of the input signal.Type: GrantFiled: June 27, 1991Date of Patent: January 26, 1993Assignee: Sony CorporationInventor: Kaoru Urata
-
Patent number: 5180814Abstract: A human monoclonal antibody having specificity for an epitope in a tumor associated antigen, said antibody produced by a cell line selected from the group consisting of Co6a3-1 (HB8493), Co7a4 (HB8494), Co28A32 (HB9380), Co16-86 (HB8496), and Co16-88 (HB8495).Type: GrantFiled: January 22, 1991Date of Patent: January 19, 1993Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 5130297Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X--MHC--peptide or MHC--peptide--X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; -- represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and -- represents a covalent bond, to noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.Type: GrantFiled: August 30, 1990Date of Patent: July 14, 1992Assignee: Anergen, Inc.Inventors: Somesh D. Sharma, L. Bernard Lerch, Brian R Clark
-
Patent number: 5130416Abstract: A histidine rich antigen, designated PfHRP-II, has been synthesized from a recombinant DNA clone containing a genomic fragment of Plasmodium falciparum. PfHRP-II is a protein exported from the parasite into the body fluid. This protein passes through the host erythrocyte in concentrated packets and is released from the infected erythrocyte into the body fluid. The antigen has been isolated and is useful for protection against malaria.Type: GrantFiled: May 3, 1990Date of Patent: July 14, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Thomas E. Wellems, Russell J. Howard
-
Patent number: 5118627Abstract: A microbial shuttle vector is disclosed which is independently replicative in bacterial cells and mammalian cells and includes in its DNA sequence bacterial plasmid sequences allowing selection and replication in bacterial cells, an SV40 viral origin of replication, and either an SV40 functional "early gene" promoter and functional "early gene" terminator or an SV40 functional "late gene" promoter and functional "late gene" terminator, the vector having a unique restriction endonuclease enzyme recognition site between the promoter and terminator for insertion of an exogenous gene. The presence of restriction endonuclease enzyme recognition sites facilitative of insertion of a viral functional "late gene" into the "early gene" promoter/terminator vector in a single step allows for conversion of the shuttle vector into a lytic vector of an exogenous gene.Type: GrantFiled: February 27, 1984Date of Patent: June 2, 1992Assignee: AmgenInventor: Jeffrey K. Browne
-
Patent number: 5116948Abstract: Islet Amyloid Polypeptide substantially free of Islet Amyloid which can be isolated from Islet Amyloid of different mammals and when isolated from humans it has the following amino acid sequence in positions 1-37: ##STR1##Type: GrantFiled: April 30, 1990Date of Patent: May 26, 1992Assignee: Regents of the University of MinnesotaInventors: Per Westermark, Kenneth H. Johnson
-
Patent number: 5112945Abstract: Subunits of the full length 37 amino acid residue human Islet Amyloid Polypeptide, and feline Islet Amyloid Polypeptide essentially free of unpolymerized amyloid are provided. Islet Amyloid Polypeptide (IAPP) may be isolated and purified from amyloid fibrils using depolymerizing agent and chromatographic techniques. The sequences of the purified Islet Amyloid Polypeptides have been determined Purified Islet Amyloid Polypeptides are suitable for induction of anti-IAPP antibodies.Type: GrantFiled: February 21, 1991Date of Patent: May 12, 1992Assignee: Regents of the University of MinnesotaInventors: Per Westermark, Kenneth H. Johnson
-
Patent number: 5109112Abstract: A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N-Gly-Val-Gln-Val-Glu-Thr-Ile-Ser-Pro- Gly-Asp-Gly-Arg-Thr-Phe-Pro-Lys- Ar g-Gly-Gln-Thr-X-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Gly-Lys-Lys-Phe-As p (wherein X is undefined). The HCB protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g., Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyzes the cis-trans isomerization of proline-containing peptide bonds.Type: GrantFiled: July 5, 1990Date of Patent: April 28, 1992Assignee: Merck & Co., Inc.Inventors: John J. Siekierka, Hsuen-Yun Hung, Marie J. Staruch, Nolan H. Sigal, Richard A. Mumford
-
Patent number: 5106746Abstract: A process for the in vitro immunization of an immuno-competent splenocyte against an immunogen comprising (a) obtaining a first human splenocyte population, (b) fractionating the first population so that the first fraction is enriched with T-cells and a second fraction is enriched with B-cells, (c) mixing together the cells from the first and second fractions to form a second population having a T-helper cell to B-cell ratio of at least 0.4, and the percentage of T-suppressor cells is essentially unchanged from the first population, and (d) culturing the second population in a medium containing human serum, an immunogen and a lymphokine or lymphokines which induce proliferation and differentiation of T and B cells.Type: GrantFiled: May 22, 1985Date of Patent: April 21, 1992Assignee: E. I. Du Pont de Nemours and CompanyInventor: May-Kin Ho